US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.88

+0.19150.49%

Post-market: 38.880.00000.00%16:10 EDT

Volume:49.35K

Turnover:1.92M

Market Cap:354.60M

PE:- -

High:38.94

Open:38.78

Low:38.66

Close:38.69

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.65

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China

Breakthrough BNCT Data: 80% Response Rate in Late-Stage Head and Neck Cancer Patients Treated at Hainan Boron Neutron Hospital

Short Covering May Boost Yen to 150 Per Dollar After Joint Intervention

Overseas Expansion Accelerates: Wall Street Bets China EV Short Squeeze Has Further to Run

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Oriole Resources bolsters board and advisory team as African gold projects advance

Global Funds Execute Historic Reversal: Dumping South Korea for Hong Kong Short Squeeze

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results

Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth

Oriole Completes Maiden Drilling at Cameroon Limestone Asset to Target Cement Market

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Wendy’s (WEN) Short Squeeze Has Cooled, but It’s Not Dead

Clas Ohlson posts double-digit summer sales growth but flags currency hedging headwinds

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ORR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.8815,"timestamp":1787601600000,"preClose":38.69,"halted":0,"volume":49352,"hourTrading":{"tag":"盘后","latestPrice":38.8815,"preClose":38.8815,"latestTime":"16:10 EDT","volume":9,"amount":350.03052,"timestamp":1787602205342,"change":0,"changeRate":0,"amplitude":0.001247},"delay":0,"changeRate":0.0049495993796848,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Post-Mkt","change":0.1915,"latestTime":"08-24 16:23:19 EDT","open":38.78,"high":38.935,"low":38.66,"amount":1915875,"amplitude":0.007108,"askPrice":38.98,"askSize":100,"bidPrice":35.56,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":38.69,"sharesOutstanding":12900000,"nav":38.21,"aum":348475200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.8815,"preClose":38.8815,"latestTime":"16:10 EDT","volume":9,"amount":350.03052,"timestamp":1787602205342,"change":0,"changeRate":0,"amplitude":0.001247},"volumeRatio":0.650046,"impliedVol":0.1458,"impliedVolPercentile":0.5316},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.650046,"shares":9120000,"dividePrice":0,"high":38.935,"amplitude":0.007108,"preClose":38.69,"low":38.66,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.8815,"eps":0,"divideRate":0,"volume":49352,"delay":0,"ttmEps":0,"open":38.78,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":38.09,"twentyDayClose":37.26,"sixtyDayClose":36.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656349575","title":"Press Release: Ideaya Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656349575","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656349575?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:00","pubTimestamp":1785837600,"startTime":"0","endTime":"0","summary":"-- Registrational OptimUM-02 trial of the darovasertib combination in. metastatic uveal melanoma  met its primary endpoint; new drug. application  filing is underway under the real-time oncology review. -- Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient. subset) and Phase 2 OptimUM-09 trial  to be. -- Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1. ADC) in small-cell lung cancer  and neuroendocrine carcinomas . -- Announced clinical collaboration with Roche to evaluate IDE892  in. cancer; targeting to initiate a Phase 1 combination trial in H2 2026. -- IDEAYA to host an R&D Day in Q4 focused on MTAP/CDKN2A, KRAS, and. -- $1.24 billion of cash, cash equivalents, and marketable securities as of. June 30, 2026; cash runway guidance into 2030 is unchanged based on. a late-breaking oral presentation at the 2026 American Society of. Clinical Oncology  meeting in Chicago, Illinois.  Data were from a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PARG","BK4195","ORR","BK4023","BK4211","PFS","IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656816825","title":"InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2656816825","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656816825?lang=en_us&edition=fundamental","pubTime":"2026-08-04 10:48","pubTimestamp":1785811680,"startTime":"0","endTime":"0","summary":"BEIJING, Aug.  03, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3337999/0/en/InnoCare-Announces-Orelabrutinib-in-Combination-with-Mesutoclax-Granted-Breakthrough-Therapy-Designation-in-China.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGDM","CDE","LU1223083913.SGD","LU1223082519.USD","SIL","LU1223082196.USD","XME","GDXJ","ORR","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112255437","title":"Breakthrough BNCT Data: 80% Response Rate in Late-Stage Head and Neck Cancer Patients Treated at Hainan Boron Neutron Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=1112255437","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112255437?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:16","pubTimestamp":1785734180,"startTime":"0","endTime":"0","summary":"CH BIOTECH SER (08037) subsidiary, Pengbo (Hainan) Boron Neutron Hospital, has released its first batch of real-world clinical data from the initial ten head and neck cancer patients treated with...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK1511","BK1219","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119935982","title":"Short Covering May Boost Yen to 150 Per Dollar After Joint Intervention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119935982","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119935982?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:00","pubTimestamp":1785726027,"startTime":"0","endTime":"0","summary":" Analysts suggest that the large accumulation of speculative short positions in the yen prior to Japan's latest market intervention could amplify the currency's rebound if traders begin to unwind...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CLSE","HEWJ","WTLS","PRMN","USDU","SHRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143143703","title":"Overseas Expansion Accelerates: Wall Street Bets China EV Short Squeeze Has Further to Run","url":"https://stock-news.laohu8.com/highlight/detail?id=1143143703","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143143703?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:48","pubTimestamp":1785725329,"startTime":"0","endTime":"0","summary":"Stronger-than-expected China new energy vehicle sales in July, alongside rising exports and easing inventory pressures, have prompted Wall Street to upgrade its outlook for automotive stock trading...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FAZ","CLSE","WTLS","ORR","PRMN","KBA","SHRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872437","title":"Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872437?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:35","pubTimestamp":1785411300,"startTime":"0","endTime":"0","summary":"Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-00","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335951/0/en/Crescent-Biopharma-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","ORR","PFS","BK4195","IND","BK4585","BK4211","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655185158","title":"Oriole Resources bolsters board and advisory team as African gold projects advance","url":"https://stock-news.laohu8.com/highlight/detail?id=2655185158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655185158?lang=en_us&edition=fundamental","pubTime":"2026-07-29 14:09","pubTimestamp":1785305368,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Oriole Resources PLC ( ($GB:ORR) ). Oriole Resources has strengthened its board and advisory team as it advance...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-resources-bolsters-board-and-advisory-team-as-african-gold-projects-advance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-resources-bolsters-board-and-advisory-team-as-african-gold-projects-advance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","GDXY","KGLD","GBUG","SHNY","ORR","GDX","BGLD","GDXD","GLDY","GLDM","GLD","GLL","GOAU","SGOL","USG","GLTR","DGP","1OZmain","UGL","DUST","DBC","BEGS","GDXJ","UYM","JNUG","PHYS","DZZ","BTGD","IAUM","GDXU","IGLD","CEF","DULL","GOLY","BAR","FGDL","XME","IAUI","IAU","OUNZ","DGZ","JDST","SGDM","RING","YGLD","AAAU","BK4207","PICK","PPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135438572","title":"Global Funds Execute Historic Reversal: Dumping South Korea for Hong Kong Short Squeeze","url":"https://stock-news.laohu8.com/highlight/detail?id=1135438572","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135438572?lang=en_us&edition=fundamental","pubTime":"2026-07-29 12:14","pubTimestamp":1785298493,"startTime":"0","endTime":"0","summary":"A remarkable shift in global capital flows is underway as international funds execute a sudden and dramatic pivot away from South Korea and back into Hong Kong stocks.Earlier this year, the consensus...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","WTLS","159740","VXUS","03033","07226","02837","09088","03423","03032","PRMN","CLSE","ORR","BK1610","03417","03067","07552","KCAI","09067","SHRT","03088","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654000439","title":"Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654000439","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654000439?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:00","pubTimestamp":1785240000,"startTime":"0","endTime":"0","summary":"Company expects to initiate enrollment in TEMPO-1 in September 2026OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/28/3334206/0/en/Corbus-Pharmaceuticals-Announces-FDA-Clearance-to-Initiate-TEMPO-1-Registrational-Study-of-CRB-701-in-Patients-with-2L-Oropharyngeal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4211","ORR","BK4588","BK4585","BK4139","CRBP","BK4080","BK4231","LABU","PFS","NETL","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPZ","BK4161","ASD","MDST","BK4585","SCD","AMLP","AMZA","EIPI","TNGY","CR","EIPX","BK4144","BK4590","BK4581","EMLP","ENFR","MLPA","NCI","BK4588","ET","BK4202","UMI","ORR","USAI","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653704593","title":"Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704593?lang=en_us&edition=fundamental","pubTime":"2026-07-24 15:20","pubTimestamp":1784877600,"startTime":"0","endTime":"0","summary":"--  Samsung Bioepis reports revenue of 847.1 billion KRW and an operating. profit of 230.6 billion KRW in the first half of 2026, recording 6%. --  Expanding direct commercialization in Europe to five products with the. launch of OPUVIZ 40 mg/mL vial, a biosimilar to Eylea1 . --  First to announce preliminary results from Phase 1, 3 clinical studies. engines through establishment of a global R&D hub in China. -----------------  -----  -----  ----------  -----  -----  ----------Business Updates--  Samsung Bioepis has expanded direct commercialization in Europe to five. expanding its commercial footprint in international markets, incl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","BK4550","ADC","BK4604","BK4231","BK4581","EMXC","IEMG","BBP","NETL","BK4099","CEO","BK4555","R","TM","BK4080","KBWY","BK4181","BK4585","BK4022","BK4232","ORR","PK","BK4504","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774076","title":"Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774076","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774076?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:03","pubTimestamp":1784851380,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 .Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, the revenue is expected to range between US$120 million  and US$125 million , representing an increase of approximately 19% to 24% compared with approximately US$101 million for the corresponding period in 2025. The profit for the Reporting Period is expected to range between US$62 million  and US$67 million . Total adjusted profit ([1]) is expected to range between US$70 million  and US$75 million .The expected revenue growth and scaled profitability are primarily attributable to:-- Continued strategic collaborations with global multinational","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","CHAT","VTHR","03160","BK1161","AIPO","BK4135","BK1574","CNS","BK4099","BK4232","ARTY","MSS","BK4585","QTOC","BK4555","BMS","BK1583","BK4113","BK4022","BK4604","ORR","TM","R","02142","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653734922","title":"Oriole Completes Maiden Drilling at Cameroon Limestone Asset to Target Cement Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2653734922","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653734922?lang=en_us&edition=fundamental","pubTime":"2026-07-22 14:12","pubTimestamp":1784700739,"startTime":"0","endTime":"0","summary":"An update from Oriole Resources PLC ( ($GB:ORR) ) is now available. Oriole Resources PLC has completed a maiden diamond drilling programme at its 8...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oriole-completes-maiden-drilling-at-cameroon-limestone-asset-to-target-cement-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oriole-completes-maiden-drilling-at-cameroon-limestone-asset-to-target-cement-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652001290","title":"Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2652001290","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652001290?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:30","pubTimestamp":1784547000,"startTime":"0","endTime":"0","summary":"Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expe","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ORR","BK4161","LAB","BK4124","CR","SMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652715280","title":"Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652715280","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652715280?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:15","pubTimestamp":1784319300,"startTime":"0","endTime":"0","summary":"Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July  17, 2026 (GLOBE NEWSWIRE) -- ZentalisPharmaceuticals, Inc. (Nasdaq: ZNTL), a cl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329282/0/en/Zentalis-Pharmaceuticals-to-Present-at-the-European-Society-for-Medical-Oncology-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4211","EPV","ORR","PFS","PROC","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652400155","title":"Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652400155","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652400155?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:15","pubTimestamp":1784286900,"startTime":"0","endTime":"0","summary":"Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/17/3329028/0/en/Evaxion-to-present-three-year-clinical-efficacy-data-for-personalized-cancer-vaccine-EVX-01-at-the-ESMO-Congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","ORR","VTHR","BK4139","CHAT","EVAX","EVX","QTOC","AIPO","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105706","title":"InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105706","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105706?lang=en_us&edition=fundamental","pubTime":"2026-07-14 19:23","pubTimestamp":1784028180,"startTime":"0","endTime":"0","summary":"BEIJING, July  14, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced that Signal Transduction and Targeted Therapy (STTT), a Nature Portfolio journal, published a pa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/14/3326726/0/en/InnoCare-Announces-Publication-in-STTT-IF-81-2-of-Phase-3-Results-Showing-Orelabrutinib-Significantly-Prolonged-Progression-Free-Survival-in-Treatment-Na%C3%AFve-CLL-SLL.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","HR","BK4211","SRET","BK4203","BK4225","BK4161","ORR","PFS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111495","title":"Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111495","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111495?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944000,"startTime":"0","endTime":"0","summary":"INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/Immutep-Provides-Clinical-Update-in-1st-line-NSCLC-Positive-Mature-Overall-Survival-Data-from-INSIGHT-003-and-Update-from-TACTI-004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ORR","INAQU","ALC","IMMP","BK4534","LU2265009873.SGD","BK4198","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607424","title":"Wendy’s (WEN) Short Squeeze Has Cooled, but It’s Not Dead","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607424","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649607424?lang=en_us&edition=fundamental","pubTime":"2026-07-07 15:38","pubTimestamp":1783409880,"startTime":"0","endTime":"0","summary":"Wendy’s ($WEN) short squeeze has cooled, but it is not dead. The fast-food chain’s shares have suddenly become one of the more interesting short-te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/wendys-wen-short-squeeze-has-cooled-but-its-not-dead?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/wendys-wen-short-squeeze-has-cooled-but-its-not-dead?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BERZ","LBAY","ORR","HDGE","DWSH","BK4209","FFLS","EVNT","LSEQ","SHRT","FTLS","WEN","CLSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649709609","title":"Clas Ohlson posts double-digit summer sales growth but flags currency hedging headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2649709609","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649709609?lang=en_us&edition=fundamental","pubTime":"2026-07-07 13:33","pubTimestamp":1783402388,"startTime":"0","endTime":"0","summary":"Clas Ohlson AB ( ($SE:CLAS.B) ) just unveiled an announcement. Clas Ohlson reported a strong start to the summer trading period, with June net sale...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/clas-ohlson-posts-double-digit-summer-sales-growth-but-flags-currency-hedging-headwinds?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/clas-ohlson-posts-double-digit-summer-sales-growth-but-flags-currency-hedging-headwinds?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HTRB","TOAK","IQDY","ORR","HEFA","SCZ","GTO","LEXI","HDMV","RTRE","TOK","ISHG","TPLS","DXIV","GHMS","AGGS","IPPP","EFZ","IBUF","DBEZ","DWMF","ISEP","IMAR","IFEB","YJUN","WBND","FTRB","FARX","HFSI","DUKH","SFGV","QEFA","PIEQ","ADFI","QINT","DGCB","HAWX","INEQ","BUFY","IQDG","TBFG","BUFI","GTR","ILOW","YDEC","NUDM","PICB","FTBD","PYLD","IOCT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":133,"code":"91000000","status":"200"}]}}